NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...

“At Intra-Cellular Therapies, we understand the lifelong debilitating struggle people with schizophrenia experience. The need for new treatment options for this community has driven our efforts to ...

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. In a statistically ...

Intra-Cellular ITCI is a commercial-stage biotech company focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The ...

The sNDA submission is based on positive results from Studies 501 and 502 demonstrating CAPLYTA’s robust antidepressant efficacy and favorable safety and tolerability profile CAPLYTA, if approved as ...

NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...

Pooled analysis of 3 randomized, double-blind, pacebo-cotrolled trials supports the safety and the distinct and favorable tolerability profile of lumateperone 42 mg Mean change from baseline in ...

“We are encouraged by CAPLYTA's strong growth trajectory in the third quarter and look forward to further growth in the remainder of 2024 and beyond. We are on track to submit our sNDA for the ...

Intra-Cellular's share price has increased by 450% over a five-year period and over 50% in the past year. The company's success is attributed to its approved drug, Caplyta, which has driven ...